OPKO has acquired rights from Taiwan’s Academia Sinica to a new technology for the development of protein-based vaccines against influenza and other viral infections.
The vaccine is expected to provide protection from multiple influenza strains, ranging from seasonal influenza to global pandemics such as swine and avian flu.
OPKO has also acquired rights from Academia Sinica to ceramide analogs that are believed to be useful as vaccines or vaccine adjuvants. These are projected to apply to a wide variety of disorders, including cancer, infectious disease, and autoimmune disease.
OPKO is currently working in conjunction with Academia Sinica to advance and develop products under these technologies.